Join BJS Academy
BJS Academy>Randomized clinical ...>Adjuvant nivolumab p...
Normal View Dyslexic View

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.

17 November 2022
Randomized clinical trials General
Livingstone E, Zimmer L, Hassel JC, Fluck M, Eigentler TK, Loquai C et al, on behalf of the Dermatologic Cooperative Oncology Group.

Lancet 2022; 10358: 1117-1129.

Some 175 patients were randomized into one of three treatment arms. After a median of 49.2 months, recurrence-free survival was 64.2 per cent after the combination of nivolumab and ipilimumab, 31.4 per cent after nivolumab alone and 15 per cent after placebo; P<0.0001. Combination treatment also improved overall survival.

Comment; Combination treatment should be standard in this group.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct175
Randomized clinical trials
Randomized clinical trials
General
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Livingstone E, Zimmer L, Hassel JC, Fluck M, Eigentler TK, Loquai C et al, on behalf of the Dermatologic Cooperative Oncology Group.
17112022
Lancet 2022; 10358: 1117-1129.
Some 175 patients were randomized into one of three treatment arms. After a median of 49.2 months, recurrence-free survival was 64.2 per cent after the combination of nivolumab and ipilimumab, 31.4 per cent after nivolumab alone and 15 per cent after placebo; P<0.0001. Combination treatment also improved overall survival.
Comment; Combination treatment should be standard in this group.
Published on: 17 November 2022
Article ID: rct175

Related articles

Intrarenal pressure with hand-pump or pressurized-bag irrigation: randomized clinical trial at retrograde intrarenal surgery.

Croghan SM, O’Meara S, Cunnane EM, Purtill H, Walsh MT, O’Brien FJ et al.

7 August 2024

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.

Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR et al.

16 August 2024

Intraoperative Wound Irrigation for the Prevention of Surgical Site Infection After Laparotomy. A randomized clinical trial by CHIR-Net.

Mueller C, Kehl V, Dimpel R, Blankenstein C, Egert-Schwender SE, Strudthoff J, Lock JF et al, for the IOWISI Study Group.

16 August 2024
Home
  • Normal view
  • Dyslexic view
Info
Copied!